The modified amino acid levacetylleucine delivered clinically meaningful results in children and adults with the rare ...
(RTTNews) - Biogen Inc. (BIIB) said that the European Commission has authorized Skyclarys (omaveloxolone) for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.
Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
The FDA approved omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia in patients ages 16 and older, making it the first approved treatment for this rare progressive neurodegenerative ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to Reata Pharmaceuticals Inc.’s new drug application for omaveloxolone to ...
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders ...
Only successful pivotal Phase III trial in Ataxia-Telangiectasia (A-T), a rare, progressive neurodegenerative disease with no approved treatments Phase III trial successfully achieved its primary ...
Ataxia is a neurological condition that disrupts muscle coordination, affecting movement, balance, and sometimes speech or vision. It can be inherited, acquired from other conditions, or occur ...
Dr. Mark Payne, a professor of pediatrics at the Indiana University School of Medicine and a pediatric cardiologist at Riley ...
Monthly infusions of an investigational product that encapsulates dexamethasone sodium phosphate into autologous erythrocytes (EryDex) appeared safe but did not significantly improve neurological ...
The first time Stephanie Miller heard the word “ataxia” was when she learned she had it. Now the Cleveland woman is doing what she can to slow its progression with a strong support system of family ...